Servier Discontinues Partnership with Allogene
On Wednesday, September 21, Allogene reported (SEC Filing) that Servier has discontinued its involvement in the development of allogeneic CD19-directed assets, including Allogene’s most advanced candidates such as ALLO-501, ALLO-501A, and UCART19. Below, Celltelligence provides insights on how the lack of an ex-US licensing partner could affect Allogene’s pipeline development.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.